MyoKardia, Inc. (MYOK) News
Filter MYOK News Items
MYOK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MYOK News From Around the Web
Below are the latest news stories about MyoKardia Inc that investors may wish to consider to help them evaluate MYOK as an investment opportunity.
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPOHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ... |
The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPOScaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than... |
MyoKardia (MYOK) Investor Presentation - SlideshowThe following slide deck was published by MyoKardia, Inc. in conjunction with this event.... |
Dosing is underway in mid-stage study for MyoKardia's danicamtiv in heart diseaseMyoKardia ([[MYOK]] +0.9%) has dosed the first patient in Phase 2 trial of danicamtiv (MYK-491) in people with primary dilated cardiomyopathy ((DCM)), characterized by weakened and enlarged heart muscle, that results in the heart not being able to pump enough blood.The 24-subject trial's primary endpoint is safety and tolerability, and secondary... |
MyoKardia inks lead drug licensing pact with LianBio in ChinaMyoKardia (MYOK) +1.3% premarket, has announced a license agreement with LianBio, for the development and commercialization of its lead drug candidate, mavacamten for hypertrophic cardiomyopathy ((HCM)) in China, other Asian territories.HCM is an inherited disorder characterized by abnormal thickening of heart muscle leading to compromised cardiac function.MyoKardia will receive an equity stake in Lian Cardiovascular, LianBio’s subsidiary and... |
MyoKardia, Inc. (MYOK) CEO Tassos Gianakakos on Q2 2020 Results - Earnings Call TranscriptMyoKardia, Inc. (MYOK) Q2 2020 Earnings Conference Call August 04, 2020, 16:30 ET Company Participants Tassos Gianakakos - President, CEO & Director Jay Edelberg - SVP, Clinical Development William Fairey - Chief Commercial Officer & EVP Taylor Harris - CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co.... |
MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and… |
Hypertrophic Cardiomyopathy Pipeline 2020 Featuring Algomedix, Celltrion, MyoKardia, Novartis and 4 Others - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "Hypertrophic Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Hypertrophic Cardiomyopathy is one of the widely researched conditions during 2020 with 8 companies actively focusing on realizing pipeline's potential. Development of Hypertrophic Cardiomyopathy medicines is identified as integral to the strateg |
MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic CardiomyopathyBRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to mavacamten, a novel, oral, allosteric modulator of cardiac myosin, for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM). The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of a drug candidate that is planned for use to treat a serious or life-threatening disease or condition when clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. “Receipt of Breakthrough Therapy Designation from the FDA acknowledges both the signific... |
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic CardiomyopathiesBRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies. |